(Q46846323)

25 December 2017

title

A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel (English)

1 reference

25 December 2017

1 reference

1 reference

1 reference

8

1 reference

25 December 2017

Mary-Ellen Taplin

5

object named as

Mary-Ellen Taplin

1 reference

25 December 2017

Tomasz M Beer

2

object named as

Tomasz M Beer

1 reference

25 December 2017

author name string

Robert W Ross

1

1 reference

25 December 2017

Susanna Jacobus

3

1 reference

25 December 2017

Glenn J Bubley

4

1 reference

25 December 2017

Christopher W Ryan

6

1 reference

25 December 2017

Jiaoti Huang

7

1 reference

25 December 2017

Prostate Cancer Clinical Trials Consortium

9

1 reference

25 December 2017

language of work or name

English

0 references

publication date

1 February 2008

1 reference

25 December 2017

number of pages

6

1 reference

inferred from page(s)

published in

Cancer

1 reference

25 December 2017

volume

112

1 reference

25 December 2017

issue

3

1 reference

25 December 2017

page(s)

521-526

1 reference

25 December 2017

cites work

Cancer statistics, 2006

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23195

7 January 2021

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23195

7 January 2021

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23195

7 January 2021

Is there a role for platinum chemotherapy in the treatment of patients with hormone-refractory prostate cancer?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23195

7 January 2021

A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23195

7 January 2021

Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23195

7 January 2021

Circulating chromogranin a and hormone refractory prostate cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23195

7 January 2021

The use of the Calvert formula to determine the optimal carboplatin dosage

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23195

7 January 2021

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23195

7 January 2021

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23195

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23195

7 January 2021

Randomized clinical trial design for assessing noninferiority when superiority is expected

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23195

7 January 2021

Carboplatin in advanced hormone refractory prostatic cancer patients.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23195

7 January 2021

Effect of carboplatin on response and palliation in hormone-refractory prostate cancer. Swiss Group for Clinical Cancer Research (SAKK).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23195

7 January 2021

Identifiers

DOI

10.1002/CNCR.23195

1 reference

25 December 2017

1 reference

25 December 2017